| Q54939484 | A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. |
| Q28479007 | A novel role for BDNF-TrkB in the regulation of chemotherapy resistance in head and neck squamous cell carcinoma |
| Q36425600 | ABT-737 synergizes with Bortezomib to kill melanoma cells |
| Q37727061 | Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma |
| Q39955638 | Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. |
| Q34069302 | Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells |
| Q39588369 | Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization |
| Q37605160 | Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics |
| Q41983817 | BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling |
| Q39645072 | BH3-only protein Bim predicts advanced stage of cutaneous melanoma |
| Q36418729 | BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma |
| Q35090029 | BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model |
| Q37883974 | Bim: guardian of tissue homeostasis and critical regulator of the immune system, tumorigenesis and bone biology |
| Q35550888 | Biomarkers as key contributors in treating malignant melanoma metastases |
| Q38237431 | Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression |
| Q33830911 | Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics |
| Q41836780 | Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. |
| Q51112339 | Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. |
| Q34334499 | Critical role of STAT3 in melanoma metastasis through anoikis resistance |
| Q39712781 | Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. |
| Q57476780 | Discovery of a small-molecule inhibitor of specific serine residue BAD phosphorylation |
| Q36439920 | Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells |
| Q35723900 | ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity |
| Q38145387 | Emerging BRAF inhibitors for melanoma. |
| Q33767083 | FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells |
| Q43127268 | Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". |
| Q53302291 | Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells |
| Q37547526 | Inhibition of Bim enhances replication of varicella-zoster virus and delays plaque formation in virus-infected cells |
| Q36931453 | Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma |
| Q37705251 | Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. |
| Q90216637 | KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells |
| Q38040353 | MAP kinase signaling and inhibition in melanoma |
| Q43119901 | Mcl-1 is required for melanoma cell resistance to anoikis |
| Q38146707 | Melanoma mutagenesis and aberrant cell signaling |
| Q39010041 | Melanoma never says die. |
| Q93007229 | Modulating Tumor Cell Functions by Tunable Nanopatterned Ligand Presentation |
| Q34052520 | Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia |
| Q38739256 | Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. |
| Q37689575 | NRAS mutant melanoma: biological behavior and future strategies for therapeutic management |
| Q37028555 | Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival |
| Q34761941 | PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression |
| Q35320304 | Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma |
| Q93366452 | Prognostic Value of NRAS Gene for Survival of Colorectal Cancer Patients: A Systematic Review and Meta-Analysis |
| Q30791975 | Receptor tyrosine kinase Met promotes cell survival via kinase-independent maintenance of integrin α3β1 |
| Q55492453 | Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). |
| Q30486572 | Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions |
| Q36954187 | Skp2 regulates G2/M progression in a p53-dependent manner |
| Q35859282 | Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies |
| Q51746852 | Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. |
| Q34165045 | The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms |
| Q35691278 | The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression |
| Q38696187 | The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas |
| Q35878248 | The current state of targeted therapy in melanoma: this time it's personal |
| Q37826353 | The extracellular matrix in digestive cancer |
| Q39803993 | The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations |
| Q37290943 | Tumour cell survival signalling by the ERK1/2 pathway |
| Q36173303 | Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer |
| Q35640196 | Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma |
| Q38466630 | Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. |
| Q37492231 | hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma |